Our first ever Parkinson’s Life poetry competition attracted entries from around the world. Ahead of our interview with the winner next week, we caught up with runner-up Marc Woodward, on everything from how Parkinson’s “crept up on him” aged 54, what’s on his ‘bucket list’ – and the inspiration behind his fantastic poem ‘San Francisco’
The global response to our first ever poetry competition was overwhelming. It was a delight to read all of our reader’s poems, and a real challenge narrowing it down to just two entries. After careful deliberation we are delighted to announce Marc Woodward, who works in financial services and is based in Devon, UK, as our runner-up.
Marc, who was diagnosed with Parkinson’s in 2016, wrote his winning poem ‘San Francisco’ while on a writing retreat in Santa Cruz, US. The poem, which deals with feelings of nostalgia, hints at symptoms of the condition and references the idea of the ‘bucket list’ – all set against the colourful backdrop of San Francisco, US – really tells a story.
We caught up with Marc, who told us about his passion for poetry and music, his experience of the condition and why he doesn’t want to be known as ‘a poet with Parkinson’s’.
Why did you enter our competition?
I write a lot of poetry anyway, and I have Parkinson’s so I thought I should have a go! I don’t enter a lot of competitions usually.
Have you been published before?
I published a collection of poetry called ‘Hide Songs’ in 2018. My poetry has also featured in various publications and journals.
Are you a full-time poet?
Unfortunately not. I work in financial services. Every poet has a day job, even the greats. T.S. Eliot was a bank manager. I think it’s good to have a day job, as you need outside stimulus instead of just burying your head in books all the time.
When were you diagnosed with Parkinson’s?
I was diagnosed in January 2016 but I had been having symptoms for years without any idea what Parkinson’s was. I noticed that when I was playing music, I wasn’t moving as smoothly as before. I couldn’t play like I used to, and I just put it down to getting old. Parkinson’s crept up on me and I didn’t even realise it.
What was the inspiration behind ‘San Francisco’?
I wrote it while on a writing residency in Santa Cruz, US, last October. In the 80s I wanted to go to San Francisco to play music, but never did, which the poem reflects on. Finally, I went last year. So, it’s to do with a bit of a ‘bucket list’ thing really.
When you have Parkinson’s, you are looking down the barrel of a gun that has been fired with a bullet coming very slowly towards you. I decided I needed to make the most of the opportunities that come a long. That’s the positive side of the disease, you think “maybe there’ll be a cure one day” but in the meantime you need to just do things that you’ve always wanted to do.
Tell me about your experience of Parkinson’s.
So far, I’m really trying to reduce stress in my life, especially work-related stress. Sadly, I don’t play gigs any more, which had been a central part of my life for a long time. I can play okay, but I can’t play like I once could. It just doesn’t feel the same anymore. Parkinson’s has knocked my self-confidence, but it has also encouraged me to (as much as it is a cliché) ‘live for the moment’.
Do you find writing an outlet for your Parkinson’s?
I’m not sure. ‘San Francisco’ was not actually meant to be about Parkinson’s. It was meant to be about San Francisco but Parkinson’s came sneaking in! I am trying to avoid writing about Parkinson’s too much really, because I don’t want it to define me. I don’t want to be the ‘poet with Parkinson’s’. I just want to be who I am.
Who is your favourite poet?
There are lots. I like Edward Thomas, the British nature writer. I love the American writer Billy Collins, and Robert Frost. When writing ‘San Francisco’ I drew inspiration from all of them, but the poem’s particular narrative, spoken style comes from Billy Collins. Most of the stuff I usually write is very nature oriented.
Marc Woodward at his writing residency in Santa Cruz, US.
‘San Francisco’ by Marc Woodward
“It’s an odd thing but anyone who disappears is said to be seen in San Francisco.” – Oscar Wilde
Sundown sets the painted ladies dancing
on the eastern side of Alamo Square.
Clustered below Monterey cypresses
silhouettes watch dime-and-quarter fog
read bedtime stories to downtown suits.
I eat at the Absinthe bar in Hayes –
tomato bisque and a yellow Sauvignon.
The hipster barman shakes cocktails
like he’s summoning a djinn.
Like he’s wrestling the palsy.
At two a.m. I awake to a siren
and lie jet-lagged, cramping.
I recall years back in Manhattan
all-night sirens attention seeking
through the sodium limbo
and a high wall of windows
blinking on and off
– as if the whole building was trying its luck
in a giant game of tic-tac-toe.
I think about chance and odds.
San Francisco is quieter, calmer. Steadier.
At nineteen I wanted to move here,
play mandolin in the New Acoustic scene.
I bought Grisman LPs, a guide to the city,
studied bucket-shop flights in the Sunday papers.
Instead I stayed home, went to work,
married and made a family album.
And though I never doubted how right that was
being here at last eases an old pain.
I’m staying in a tall, bay-windowed Italianate
owned by a thin guy called Mike
– and Willy, his lilac poodle.
Mike has a harmonium and a baby grand.
They smile toothily at each other
across the Victorian drawing room
like the two gay lodgers who appear for breakfast
passing coffee back and forth across the table.
We chat about the downtown homeless and trams.
I sit on my trembling left hand.
The one which stumbles on frets where once it flew.
Insurance money in my jeans, I plan my last day in town.
Provençale-style aubergine stuffed with ratatouille and vegetarian mince
Provençale dish with vegetarian mince served in half an aubergine
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.